Skip to main content

Can-Fite BioPharma Ltd.

CANF
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001536196

No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.

13F holders, Q3 2023

Institutional positions in Can-Fite BioPharma Ltd. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
9
+2 vs. Q2 2023
Shares held
67.7K
+13.0K (+23.8%) vs. Q2 2023
Total value
$179.2K
+$11.4K (+6.8%) vs. Q2 2023
New holders
2
1 more added
Sold out
0
1 more reduced

Compare with Q2 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting CANF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2023: 9 institutions
Q1 2021: 15 institutionsQ2 2021: 12 institutionsQ3 2021: 12 institutionsQ4 2021: 15 institutionsQ1 2022: 13 institutionsQ2 2022: 12 institutionsQ3 2022: 12 institutionsQ4 2022: 11 institutionsQ1 2023: 9 institutionsQ2 2023: 7 institutionsQ3 2023: 9 institutionsQ4 2023: 9 institutionsQ1 2024: 8 institutionsQ2 2024: 11 institutionsQ3 2024: 12 institutionsQ4 2024: 13 institutionsQ1 2025: 14 institutionsQ2 2025: 16 institutionsQ3 2025: 16 institutionsQ4 2025: 16 institutionsQ1 2026: 14 institutionsQ2 2026: 8 institutions
Value heldQ3 2023: $179.2K
Q1 2021: $1.09MQ2 2021: $1.05MQ3 2021: $2.43MQ4 2021: $626.5KQ1 2022: $472.3KQ2 2022: $464.7KQ3 2022: $380.5KQ4 2022: $262.2KQ1 2023: $843.5KQ2 2023: $167.8KQ3 2023: $179.2KQ4 2023: $536.4KQ1 2024: $1.06MQ2 2024: $1.62MQ3 2024: $1.52MQ4 2024: $185.9KQ1 2025: $193.9KQ2 2025: $950.1KQ3 2025: $952.6KQ4 2025: $78.3KQ1 2026: $428.6KQ2 2026: $149.1K
Institutions holding CANF and their total value by quarter
QuarterHoldersValue
Q2 20268$149.1K
Q1 202614$428.6K
Q4 202516$78.3K
Q3 202516$952.6K
Q2 202516$950.1K
Q1 202514$193.9K
Q4 202413$185.9K
Q3 202412$1.52M
Q2 202411$1.62M
Q1 20248$1.06M
Q4 20239$536.4K
Q3 20239$179.2K
Q2 20237$167.8K
Q1 20239$843.5K
Q4 202211$262.2K
Q3 202212$380.5K
Q2 202212$464.7K
Q1 202213$472.3K
Q4 202115$626.5K
Q3 202112$2.43M
Q2 202112$1.05M
Q1 202115$1.09M

Institutions, Q3 2023

Shares, value and share of portfolio for each institution holding Can-Fite BioPharma Ltd.; share changes are against Q2 2023.

Institutions holding CANF in Q3 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Morgan Stanley33,007$87.5K0.00%−300−0.9%Reduced
Rhumbline Advisers17,922$47.5K0.00%+820+4.8%Added
Susquehanna International Group, LLP12,047$31.9K0.00%+12,047New
Fifth Third Bancorp3,000$7.95K0.00%00.0%Unchanged
National Bank of Canada600$1.48K0.00%00.0%Unchanged
Citigroup Inc553$1.47K0.00%00.0%Unchanged
JPMorgan Chase & Co460$1.22K0.00%+460New
Federation des caisses Desjardins du Quebec53$1400.00%00.0%Unchanged
TD Waterhouse Canada Inc.20$670.00%00.0%Unchanged